Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.

Mahévas M, Patin P, Huetz F, Descatoire M, Cagnard N, Bole-Feysot C, Le Gallou S, Khellaf M, Fain O, Boutboul D, Galicier L, Ebbo M, Lambotte O, Hamidou M, Bierling P, Godeau B, Michel M, Weill JC, Reynaud CA.

J Clin Invest. 2013 Jan;123(1):432-42. doi: 10.1172/JCI65689. Epub 2012 Dec 17.

2.

Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab.

Mahévas M, Michel M, Vingert B, Moroch J, Boutboul D, Audia S, Cagnard N, Ripa J, Menard C, Tarte K, Mégret J, Le Gallou S, Patin P, Thai L, Galicier L, Bonnotte B, Godeau B, Noizat-Pirenne F, Weill JC, Reynaud CA.

J Autoimmun. 2015 Aug;62:22-30. doi: 10.1016/j.jaut.2015.05.006. Epub 2015 Jun 23.

PMID:
26112660
3.

Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia.

Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, van den Broek T, Facy O, Ortega-Deballon P, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Samson M, Trad M, Lorcerie B, Janikashvili N, Saas P, Bonnotte B, Radstake TR.

Blood. 2014 Oct 30;124(18):2858-66. doi: 10.1182/blood-2014-03-563445. Epub 2014 Sep 16.

4.

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Schweizer C, Reu FJ, Ho AD, Hensel M.

Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.

PMID:
17622529
5.

Both splenic CD5(+) B and CD5(-) B cells produce platelet glycoprotein-specific autoantibodies in chronic ITP.

Hou M, Lv B, He Q, Lu L, Shi Y, Ji X, Ma D, Zhang M.

Thromb Res. 2003 Apr 15;110(1):1-5.

PMID:
12877901
6.

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.

Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.

Am J Ther. 2013 Mar-Apr;20(2):219-22. doi: 10.1097/MJT.0b013e318258905e.

PMID:
23466621
7.

The pathogenesis of chronic immune thrombocytopenic purpura.

McMillan R.

Semin Hematol. 2007 Oct;44(4 Suppl 5):S3-S11. doi: 10.1053/j.seminhematol.2007.11.002. Review.

PMID:
18096470
8.

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.

Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, Ciudad M, Leguy V, Berthier S, Petrella T, Aho-Glélé S, Martin L, Maynadié M, Lorcerie B, Rat P, Cheynel N, Katsanis E, Larmonier N, Bonnotte B.

Blood. 2011 Oct 20;118(16):4394-400. doi: 10.1182/blood-2011-03-344051. Epub 2011 Aug 29.

9.

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

Audia S, Samson M, Mahévas M, Ferrand C, Trad M, Ciudad M, Gautheron A, Seaphanh F, Leguy V, Berthier S, Salles B, Martin L, Lorcerie B, Ortega-Deballon P, Facy O, Caillot D, Soudry-Faure A, Michel M, Godeau B, Larmonier N, Saas P, Janikashvili N, Bonnotte B.

Blood. 2013 Oct 3;122(14):2477-86. doi: 10.1182/blood-2013-03-491415. Epub 2013 Aug 20.

10.

Current therapies in primary immune thrombocytopenia.

Pels SG.

Semin Thromb Hemost. 2011 Sep;37(6):621-30. doi: 10.1055/s-0031-1291372. Epub 2011 Nov 18. Review.

PMID:
22102265
11.

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.

Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L.

Am J Hematol. 2015 Apr;90(4):301-5. doi: 10.1002/ajh.23930. Epub 2015 Mar 2.

12.

Increased number of B-cells in the red pulp of the spleen in ITP.

Olsson B, Ridell B, Jernås M, Wadenvik H.

Ann Hematol. 2012 Feb;91(2):271-7. doi: 10.1007/s00277-011-1292-2. Epub 2011 Jul 23.

PMID:
21785982
13.

The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia.

Aslam R, Kapur R, Segel GB, Guo L, Zufferey A, Ni H, Semple JW.

Exp Hematol. 2016 Oct;44(10):924-930.e1. doi: 10.1016/j.exphem.2016.07.004. Epub 2016 Jul 12.

PMID:
27417974
14.

The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura.

Sandler SG.

Semin Hematol. 2000 Jan;37(1 Suppl 1):10-2. Review.

PMID:
10676918
15.

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.

Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U.

Int J Hematol. 2006 Jul;84(1):48-53.

PMID:
16867902
16.

Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.

Clausen MR, Segel E, Brandsborg M, d'Amore F.

Eur J Haematol. 2011 Mar;86(3):256-9. doi: 10.1111/j.1600-0609.2010.01561.x. Epub 2011 Jan 11.

PMID:
21166717
17.

Immune thrombocytopenia: no longer 'idiopathic'.

McCrae K.

Cleve Clin J Med. 2011 Jun;78(6):358-73. doi: 10.3949/ccjm.78gr.10005. Review.

18.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB.

Blood. 2012 Jun 21;119(25):5989-95. doi: 10.1182/blood-2011-11-393975. Epub 2012 May 7.

19.
20.

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Flint SM, Gibson A, Lucas G, Nandigam R, Taylor L, Provan D, Newland AC, Savage CO, Henderson RB.

Haematologica. 2016 Jun;101(6):698-706. doi: 10.3324/haematol.2015.137273. Epub 2016 Mar 11.

Supplemental Content

Support Center